RF Bio Partners with Banobagi Plastic Surgery Clinic for "Overseas Expansion Cooperation"

[Asia Economy Reporter Hyunseok Yoo] RF Tech announced on the 22nd that its subsidiary RF Bio has signed a comprehensive business partnership agreement with Banobagi Plastic Surgery. The two companies plan to strengthen mutual cooperation for research and development, marketing, and overseas expansion of medical aesthetic products such as fillers.

Banobagi Plastic Surgery is a leading cosmetic surgery medical institution in Korea, celebrating its 20th anniversary this year. Since its establishment, it has successfully maintained its reputation, earning recognition as a representative brand in the field of plastic surgery.

Through this agreement, both parties will actively collaborate on the research and development of medical aesthetic products, including RF Bio’s hyaluronic acid (HA) filler ‘Youthfill.’ In addition to academic support from Banobagi’s excellent medical staff for the development of RF Bio’s next-generation product line, mutual cooperation for Banobagi’s overseas expansion is also planned.

A representative from Banobagi Plastic Surgery stated, “Before the COVID-19 pandemic, overseas patients accounted for 50% to 60% of our total patients, demonstrating the great potential of ‘K-Medi.’ Based on this business agreement, we plan to combine the strengths of both sides to globalize K-Medi and K-Bio,” emphasizing the plan.

An RF Bio representative said, “Since Korea is recognized as an advanced country in the field of cosmetic medicine, products that have succeeded in gaining high recognition domestically have significant demand overseas. Youthfill, in cooperation with Banobagi, is expected to rapidly increase its market share both domestically and internationally,” adding.

RF Bio is a newly established company spun off from RF Tech in April, with its main businesses including the hyaluronic acid (HA) filler ‘Youthfill’ and anesthetic cream ‘YouSkin.’ Recently, it succeeded for the first time in the world in isolating and identifying a botulinum strain from honey, and is actively advancing the development of neurotoxin pharmaceuticals.

This content was produced with the assistance of AI translation services.